AbbVie has won its fight to keep Botox out of Medicare's drug price negotiation program, after a federal judge ruled the wrinkle-smoothing treatment qualifies for an exemption under the Inflation Reduction Act. The decision turns on an unlikely detail buried in the drug's chemistry: a protein derived from human blood plasma that the court says is essential to making Botox at all.
Judge Sides With AbbVie Over Plasma-Derived Ingredient
AbbVie Inc. secured a win in its fight against the Trump administration's decision to select its Botox drug for price negotiations, according to Bloomberg Law. U.S. District Judge Carl J. Nichols found that because one of Botox's core components is derived from human plasma, the drug as an aggregated biological product is subject to exclusion from the Centers for Medicare & Medicaid Services' negotiation program. Nichols did not mince words about the agency's handling of the exemption, saying, “CMS applied an erroneous interpretation of that exclusion.”
The component at the center of the case is HSA, a protein obtained from human blood plasma that the court found is necessary to manufacture the drug, according to VitalLaw. The ruling put it bluntly: “without HSA, one cannot make BOTOX.” That finding gave AbbVie the legal hook it needed to argue Botox should never have been treated like an ordinary drug for pricing purposes.
Dispute Traces Back to 2028 Pricing Year Selection
The fight began after CMS placed Botox on the selected drug list for the 2028 drug-pricing year, the same VitalLaw account notes. That listing would have required AbbVie to negotiate a price for the treatment, which is used both cosmetically and for a range of medical conditions. AbbVie pushed back by filing a complaint against the Department of Health and Human Services, CMS, and federal officials, including Robert F. Kennedy Jr. and Mehmet Oz, in the U.S. District Court for the District of Columbia on February 11, 2026, per court records on CourtListener.
The case is docketed as AbbVie Inc. v. U.S. Department of Health and Human Services, case number 1:26-cv-00431, in the District of Columbia, the docket shows. As Crain's Chicago Business reported, the ruling marks a win for AbbVie in its broader effort to shield Botox from the Medicare negotiation process established under the Inflation Reduction Act.
VitalLaw Dates Ruling to October 29
VitalLaw's report places the ruling on October 29, 2026, while a separate account from Law360, published October 30, 2026, reports that CMS cannot subject AbbVie's Botox to Medicare price negotiations under the Inflation Reduction Act.
It remains unclear whether the ruling will be appealed or how CMS and HHS plan to respond, and the broader practical effects on Medicare pricing and future drug selections have not been established. For now, the decision stands as a notable setback for the administration's push to apply negotiated pricing to one of AbbVie's best-known products.
